Website Search
ID 15043

Bloodcount returns to normal with Gleevec, Bud and Yvonne

Description:
Interviewee: Bud and Yvonne. CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal. (DNAi Location: Applications > Genes and medicine > drug design > Bud's Story > A Breakthrough)
Transcript:
Yvonne: Okay this is a chart of blood – white blood counts that was taken – this is about a year before he started, at that time it was known as STI-571. Bud: Yes that's it. Yvonne: And he was in the 35/50,000 range. 60,000. Bud: White blood count. Yvonne: And the white blood count which is normally I think it's about 10,000 is about the highest a person would get on it. Then he started taking this STI-571 which is Gleevec™ and about 17 days he was back down into his normal range on his white blood count and he's been normal ever since. And this is just what an important thing – what a breakthrough, I don't know what else to call it.
Keywords:
chronic myeloid leukemia,white blood count,white blood counts,white blood cells,bud white,blood cell count,white blood cell,sti 571,gleevec,location applications,romine,white blood cell count,cml,interviewee,yvonne,leukemia,genes,breakthrough,bloodcount,medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

16105. The magic pills, Bud and Yvonne
Yvonne talks about the magic pills Bud took.
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
1012. Diagnosis, Targeted therapies: Targeting activators
In this section learn that tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
1010. Diagnosis, Targeted therapies
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15058. The first clinical success with Gleevec, Brian Druker
Brian Druker talks about Bud, the first patient restored to health by Gleevec™.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving